Clinical effectiveness and safety of a Desmodium adscendens-based product, Asmodium, as an anti-asthmatic agent.

Ronald Yeboah0 个研究点目标入组 60 人开始时间: 2022年4月3日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•1.Male and female patients within the age range of 15 - 45 years with severe, moderate or mild asthma defined as an Asthma Score Questionnaire (ASQ) score of 30-20: Severe asthma, 19-10: Moderate asthma, 10-0: Mild asthma.
•2.Patients diagnosed with asthma defined as subjects with medical and physical evidence of recurrent episodes of reversible airflow obstruction for at least six (6) months. These signs and symptoms of airway hyper responsiveness include wheezing, cough, chest tightness and shortness of breath (often worse at night).
•3.A forced expiratory volume (FEV1) in 1 second of 50% to 90 % of predicted or a 12% increase in the baseline of FEV1 after the administration of a ß-agonist.
•4.Ability to comply with protocol and complete written informed consent process to participate in the trial.

•1.Patients with Chronic Obstructive Pulmonary Disease (COPD). E.g., emphysema and bronchitis.
•2.Patients with current and/or recurrent chest infections after a radiograph.
•3.Patients who have been diagnosed as status asthmaticus.
•4.Patients who are on steroidal drugs and theophylline within the past month.
•5.Pregnant and lactating mothers.
•6.Patients with chronic liver or kidney disease.

发起方

Ronald Yeboah